AstraZeneca stock gains oncology lift from EU Enhertu approval

AstraZeneca's Enhertu won European Union approval on October 27 for adjuvant treatment of adults with resected HER2-positive early breast cancer who retain invasive disease after neoadjuvant therapy. The European Commission decision, described in AstraZeneca's official announcement, marks the medicine's first EU approval in a curative-intent early breast cancer setting.

AstraZeneca stock traded at 167.00 euros on Lang & Schwarz at 10:51 CET on Tuesday, November 10, 2026. The quote is presented without a daily direction because a compatible dated Xetra closing comparison was not established.

Clinical data support earlier treatment

The approval covers patients whose tumours were surgically removed but who still have residual invasive disease after taxane-based and HER2-targeted treatment before surgery. Enhertu, also known as trastuzumab deruxtecan, is jointly developed and commercialised by AstraZeneca and Daiichi Sankyo.

The regulatory decision rests on the global DESTINY-Breast05 Phase III trial. In the study, Enhertu reduced the risk of invasive disease recurrence or death by 53% compared with trastuzumab emtansine, or T-DM1. The reported hazard ratio was 0.47, with a 95% confidence interval of 0.34 to 0.66 and a p-value below 0.0001.

Three-year invasive disease-free survival reached 92.4% for patients receiving Enhertu, compared with 83.7% for those receiving T-DM1. AstraZeneca said the safety profile was consistent with the medicine's known profile and that no new safety concerns were identified.

Milestone payment limits near-term sales impact

The approval triggers a 75 million US dollar milestone payment from AstraZeneca to Daiichi Sankyo for the adjuvant indication. The companies' commercial arrangement also means that Daiichi Sankyo recognises sales of Enhertu in most European Union territories. The regulatory win therefore expands the product's addressable use but does not translate directly into equivalent AstraZeneca revenue.

Enhertu is now approved in more than 35 countries for this adjuvant use based on DESTINY-Breast05. AstraZeneca is also evaluating the drug across several HER2-driven cancers and treatment settings, giving the decision strategic importance beyond the immediate label expansion.

For investors, the approval adds another regulatory milestone to AstraZeneca's oncology pipeline and supports the company's strategy of moving established medicines into earlier disease stages. Commercial contribution will depend on uptake, local reimbursement and the split of economics with Daiichi Sankyo, while the milestone payment creates a defined near-term cost rather than sales.

Broader UK market sentiment remains relevant for AstraZeneca stock; investors can follow the FTSE 100 for the surrounding market environment.

Further pipeline developments and regulatory decisions may shape the next phase for AstraZeneca stock. See More news and analyses on AstraZeneca stock.